MICHAEL BREEN

Corporate Board Profile

Tech Score: 0/100

← Back to All Directors

GT Biopharma, Inc.

Filing Date Source Excerpt
2022-04-29 Mr. Breen was appointed to our Board of Directors on January 13, 2021, was appointed Executive Chairman of the Board on November 8, 2021 and was appointed as our Interim Chief Executive Officer on March 2, 2022. Prior to joining our company, Mr. Breen served as a senior partner in the global law firm of Clyde & Co., specializing in all aspects of corporate law, including mergers and acquisitions and fund management regulatory issues.
2022-08-17 Michael Breen, Executive Chairman of the Board and Interim Chief Executive Officer.
2023-05-01 Mr. Breen was appointed to our Board of Directors on January 13, 2021, was appointed Executive Chairman of the Board on November 8, 2021 and was appointed as our Interim Chief Executive Officer on March 2, 2022. Prior to joining our company, Mr. Breen served as a senior partner in the global law firm of Clyde & Co., specializing in all aspects of corporate law, including mergers and acquisitions and fund management regulatory issues.
2023-11-06 Michael Breen Executive Chairman of the Board and Interim Chief Executive Officer
2024-04-29 Mr. Breen was appointed to our Board of Directors on January 13, 2021, was appointed Executive Chairman of the Board on November 8, 2021 and was appointed as our Interim Chief Executive Officer on March 2, 2022. Prior to joining our company, Mr. Breen served as a senior partner in the global law firm of Clyde & Co., specializing in all aspects of corporate law, including mergers and acquisitions and fund management regulatory issues.

Data sourced from SEC filings. Last updated: 2025-07-01